CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2020	Sep. 30, 2019
Current assets:
Cash and cash equivalents	$ 8,662,889	$ 558,988
Accounts receivable, net of allowance of $4,500 at March 31, 2020 and September 30, 2019, respectively	549,123	839,951
Inventories	88,941	142,629
Prepaid expenses and other current assets	678,120	604,740
Total current assets	9,979,073	2,146,308
Property and equipment, net	265,400	226,221
Other assets:
Deferred offering costs		109,698
Deposits	76,085	62,351
Goodwill	285,386	285,386
Intangible assets, net	720,953	734,771
Total Assets	11,326,897	3,564,735
Current liabilities:
Accounts payable and accrued liabilities (including related party of $40,000 at March 31, 2020)	1,178,358	1,616,997
Deferred revenue	671,526	628,993
Total current liabilities	1,849,884	2,245,990
Long term accrued liabilities	722,564	621,970
Secured convertible notes payable, related party. net of debt issuance costs	1,485,673	1,442,497
Secured convertible notes payable, recorded at fair value		102,777
Total liabilities	4,058,121	4,413,234
Commitments and contingencies
Applied DNA Sciences, Inc. Stockholders' Equity (Deficit):
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2020 and September 30, 2019, respectively
Common stock, par value $0.001 per share; 500,000,000 shares authorized; 4,059,943 and 1,207,993 shares issued and outstanding as of March 31, 2020 and September 30, 2019, respectively	4,060	1,208
Additional paid in capital	269,693,833	255,962,922
Accumulated deficit	(262,423,267)	(256,805,589)
Applied DNA Sciences, Inc. stockholders' equity (deficit):	7,274,626	(841,459)
Noncontrolling interest	(5,850)	(7,040)
Total equity (deficit)	7,268,776	(848,499)
Total liabilities and equity (deficit)	11,326,897	3,564,735
Series A Preferred Stock [Member]
Applied DNA Sciences, Inc. Stockholders' Equity (Deficit):
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2020 and September 30, 2019, respectively
Series B Preferred Stock [Member]
Applied DNA Sciences, Inc. Stockholders' Equity (Deficit):
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2020 and September 30, 2019, respectively